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Fig. 3.
Conclusion: Our ﬁndings indicate that a deletion of Bim/Bid can reduce
but not prevent chondrocyte apoptosis in response to mechanical injury.
Our results are consistent with previous ﬁnding where a nitric oxide
scavenger was able to reduce the incidence of chondrocyte apoptosis
after traumatic injury. Since Bim (mitochondrial intrinsic) pathway has
been shown to play a role in mediating nitric oxide induced apoptosis
it is assumed that the Bim deletion also works through this mechanism.
Additional studies are ongoing to determine whether these ﬁndings are
due to a delay in the occurrence of apoptosis or long-term (>48 hours)
prevention of chondrocyte apoptosis.
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PERIOSTIN, AN OSTEOBLAST STIMULATING FACTOR, REGULATES
CARTILAGE METABOLISM VIA MMP-13 ACTIVATION
M. Attur1, G. Palmer1, Y. Tachida2, S. Kumakura2, K. Shimada2,
S.B. Abramson1. 1NYUHosp. for Joint Diseases, New York, NY, USA;
2Daiichi-Sankyo Co. Ltd., Tokyo, Japan
Purpose: Periostin (POSTN), a gamma-carboxylated extracellular matrix
protein originally identiﬁed as an osteoblast stimulating factor. This study
investigates its expression in OA cartilage and regulation of chondrocyte
metabolism.
Methods: Cartilage slices were obtained from the advanced OA patients
(age 45–80 years) undergoing knee replacement surgery. Non-arthritic
knee cartilages were obtained from autopsy patients within 24h (NDRI,
Philadelphia). Predesigned TaqMan PCR primers were purchased from
Applied Biosystems. Lentiviral shRNA targeting POSTN were purchased
from Sigma. Matrix metalloproteinases proMMP-1 and proMMP-13 ELISA
kits were from R&D Systems. Degradation products of type II collagen
was measured using CTX II-based assay kit.
Results: We studied the expression of POSTN in pools (n = 10) of OA and
age-matched non-diseased cartilage using U133 Affymetrix microarray.
POSTN was overexpressed 2–4 fold in OA cartilage (p < 0.035) compared
to non-diseased controls. Veriﬁcation by real-time PCR conﬁrmed POSTN
upregulation. Surgical-induction of OA in rats by anterior cruciate
ligament transection (ACLT) and destabilization of the medial meniscus
(DMM) models also signiﬁcantly increased POSTN (3–11 fold) from
2–8 weeks after surgery. In OA chondrocytes isolated from human tibial
cartilage, POSTN mRNA levels, determined by qPCR, were inhibited 3-fold
in the presence of inﬂammatory cytokines IL-1b and TNFa. In contrast,
TGFb-1 (2 ng/ml) signiﬁcantly increased POSTN expression (2–40-fold). In
functional assays, exogenously added (1–30 ug/ml) or overexpression of
POSTN signiﬁcantly increased MMP-13 expression and activity (p < 0.02)
in primary human OA, rat and bovine chondrocytes. Conversely; knock
down of endogenous POSTN using targeted lentiviral shRNAs signiﬁcantly
decreased MMP-13 expression in the presence of TGF-b1. In OA cartilage
explants cultures, PSTN increased cartilage degeneration, evidenced by
increased release of collagen (C1, 2C) and GAG fragments in culture
supernatants. To determine whether PSTN is a hypertrophic marker
of chondrocytes we examined its expression in chondrogenesis assays
using human bone marrow-derived MSCs and immature murine costal
chondrocytes undergoing maturation. In both assays PSTN expression
was upregulated in a time-dependent manner, and expression coincided
with MMP-13, Alkaline Phosphatase and F-spondin. These ﬁndings
suggest that PSTN expression is associated with chondrocyte terminal
differentiation.
Conclusions: Together, these studies indicate that PSTN is a marker of
OA cartilage and chondrocyte hypertrophy. In OA, PSTN may contribute
to disease pathogenesis by promoting cartilage degradation via induction
of MMP-13.
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NATURAL HISTORY OF BONE AND CARTILAGE CHANGES IN
OSTEOARTHRITIS IN GENETIC STRAINS OF MICE
S. Hashimoto, M.F. Rai, J.M. Cheverud, L.J. Sandell. Washington Univ. Sch.
of Med., St. Louis, MO, USA
Purpose: Emerging evidence indicates that 50–75% of variation in OA
is genetic, however, little evidence is available on the genes that cause
OA or protect from OA. It has been demonstrated that speciﬁc strains of
mice (MRL/MpJ and DBA/1) are protected from post-traumatic arthritis
in young animals and age-related OA in older animals.
In the present study, selected recombinant inbred (RI) lines of SM/J
mice and LG/J were used; strains 6 and 33. RI strains are genetically
identical but each strain is a different recombination of the parental
genotypes, so we can predict that their outcomes are due to different
composition of the genome. Strain 6 and 33 were chosen because they
represent extremes of healing ability in the RI population. Preliminary
data indicated that strain 6 could heal an ear hole punch while strain
33 could not. The aim of this study is to compare the strain-dependent
development of OA following DMM surgery, assessed by measurements
of cartilage and bone over time. We also correlated the development of
OA with ear tissue regeneration potential and ability to repair cartilage.
Methods: Selected RI strains (strain 6 and 33) were subjected to
destabilization of medial meniscus (DMM) at 10 weeks of age in
right knee joint by transection of the medial meniscotibial ligament.
Cartilage degeneration was evaluated with histological sections stained
with Toluidine blue and scored with scoring system at 2, 4, and
8 weeks after surgery (n =8 at each time point). Bone changes
were analyzed with micro-computed tomography (micro-CT) scanner
at the same time-points as histological evaluation. The following
morphometric parameters of the tibial subchondral plate were calculated
for subchondral bone thickness, and trabecular bone compartments:
trabecular bone volume fraction, trabecular thickness and trabecular
connective density.
Fig. 1. (A) histological OA score of strains 6 and 33. (B) Subchondral bone
thickness in medial tibial plateau of strains 6 and 33. (*p < 0.05).
Results: Histological sections showed more cartilage degeneration in
strain 33 than strain 6 mice after DMM surgery. For the summed OA
score, strain 33 mice developed OA in a time-dependent manner and
signiﬁcantly higher grade of OA than strain 6 mice after 4 and 8 weeks of
DMM surgery (Figure 1A). Strain 33 showed subchondral bone thinning
in early time points (2 and 4 weeks), however the subchondral bone
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signiﬁcantly thickened compared to sham knee joints at 8 weeks after
surgery. In contrast, strain 6 mice showed thinning at all time points
(Figure 1B). Strain 6 mice showed signiﬁcantly lower bone volume
fraction at all time points, while in strain 33 mice bone volume was
lower only at 4 weeks and reversed from 4 to 8 weeks. Trabecular
thickness was less in strain 6 mice at all time points, but only at 4 weeks
in strain 33 mice with thickening at 8 weeks. The trabecular connective
density, which calculates the number of trabecular bone connections,
showed strain 33 mice looses trabecular bone at 4 weeks and thickens
by 8 weeks after surgery, while trabecular bone loss was observed in all
time points in strain 6 mice.
Conclusions: Strain 33 mice, which have poor healing ability for soft
tissues like ear hole, demonstrated a natural history of OA development:
they initially have bone loss, then cartilage loss followed by bone sclerosis
in the late stage of OA. In contrast, strain 6 mice, which have a good
healing ability in tissue, were protected against OA and showed bone
loss in all time points. These results suggest that cartilage and bone
changes associated with OA development are linked each other and
suggest that cartilage loss leads to subchondral bone thickening. In other
studies currently underway in our laboratory, we have found that strain
6 can repair a full thickness cartilage injury, while strain 33 cannot repair
its cartilage (Table 1). Therefore, our studies demonstrate a signiﬁcant
correlation between ear punch healing, cartilage repair and resistance to
OA in these genetic strains of mice.
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ORAL CALCITONIN DEMONSTRATED SYMPTOM-MODIFYING EFFICACY
AND INCREASED CARTILAGE VOLUME: RESULTS FROM A 2-YEAR
PHASE 3 TRIAL IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE
M.A. Karsdal1, P. Alexandersen2, M.R. John3, J. Loefﬂer3, M. Arnold3,
M. Azria3, I. Byrjalsen1, B.J. Riis1, C. Christiansen1, CCBR 2301
Investigators. 1Nordic BioSci., Herlev, Denmark; 2Orla Lehmannsgade, Vejle,
Denmark; 3Novartis Pharma, Basel, Switzerland
Purpose: To evaluate the symptom- and structure-modifying efﬁcacy and
safety of oral salmon calcitonin (oCT) formulated with a 5-CNAC carrier
(a molecule based on Eligen® technology from Emisphere), in patients
with moderate to severe knee pain and structural damages classiﬁed as
Kellgren-Lawrence 2–3 due to osteoarthritis (OA).
Methods: A total of 1169 men and women aged 50–80 years with
a mean BMI of 28.9 kg/m2 who had painful OA of the knee with
structural manifestations were enrolled in this multi-center, double-
blind, randomized placebo-controlled study. Patients received (1:1) oCT
0.8mg twice daily or placebo for 24 months; rescue medication was
allowed in both arms. The primary efﬁcacy endpoints were joint-space
width (JSW), WOMAC pain and function visual analogue scale scores after
24 months in the signal knee. Secondary endpoints included but were not
limited to WOMAC stiffness, patient and physician global assessments,
and knee cartilage degradation. Safety endpoints were adverse events
(AEs) and tolerability.
Results: Baseline values were well matched between the two groups.
In ITT analysis at 24 months, oCT treatment did not have an effect
on JSW (p=0.97; progression was −0.2mm in both groups). However,
oCT increased cartilage volume by a mean 4.8% (0.73%) [vs 2.5% (0.61%)
in placebo group, p = 0.012]. Furthermore, oCT resulted in signiﬁcant
changes (vs placebo) in WOMAC pain [−115.7 (4.9) vs −94.9 (4.8) mm;
p=0.002], function [−338.7 (16.7) vs −283.0 (15.8) mm; p=0.013] (see
Figure) and stiffness [−44.1 (2.2) vs −32.6 (2.1) mm; p < 0.001] scores
(numbers in parentheses are standard errors). Improvement was also
obtained in the oCT group (vs placebo) in VAS 24 hour pain (p = 0.018),
patient global assessment (p =0.008) and physician global assessment
(p = 0.014). The discontinuation rate was 33% for oCT vs 23% for placebo
treatment. Drug-related AE discontinuations occurred in 19.5% oCT group
(vs 5.8% in placebo group), mostly happening early in the oCT group
then parallel to placebo. The most common AEs in the oCT group (vs
placebo) were hot ﬂush (17.8 vs 4.1%), nausea (14 vs 3.1%), dyspepsia
(10.1 vs 4.5%) and diarrhoea (9.6 vs 4.3%), and accounted for most
discontinuations. Immunogenicity was noted in 17.4% (oCT) vs 1.6%
(placebo) at 24 months.
Figure: Select efﬁcacy variables: mean changes over two years.
Conclusions: Twice daily oCT over 2 years resulted in a signiﬁcant
symptom-modifying efﬁcacy in patients with painful knee OA as assessed
by WOMAC pain, physical function, and stiffness scores. Although
improvement on the primary endpoint of JSW was not reached, there
was an increase in cartilage volume vs placebo indicating some structure-
modifying efﬁcacy. Safety and tolerability of oCT was largely in line with
previous clinical experience with calcitonins.
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A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,
MULTICENTER STUDY OF RHFGF18 ADMINISTERED
INTRAARTICULARLY USING SINGLE OR MULTIPLE ASCENDING
DOSES IN PATIENTS WITH PRIMARY KNEE OSTEOARTHRITIS (OA),
NOT EXPECTED TO REQUIRE KNEE SURGERY WITHIN 1 YEAR
R. McPherson1, K. Flechsenhar2, S. Hellot2, F. Eckstein3,4. 1PAREXEL Early
Phase, Port Elizabeth, SOUTH AFRICA; 2Merck Serono S.A. (an afﬁliate of
Merck KGaA, Darmstadt, Germany), Geneva, Switzerland; 3Paracelsus Med.
Univ., Salzburg, Austria; 4Chondrometrics GmbH, Ainring, Germany
Purpose: There are no disease-modifying OA drugs (DMOAD) – a
continuing unmet need. In OA, levels of growth factors (key regulators
of chondrocyte activity) decline with age, thus reducing cartilage
maintenance and ability to resist mechanical stress. Fibroblast growth
factor 18 (FGF18) is a chondrogenic factor that promotes chondrocyte
proliferation and stabilization of the ’healthy’ anabolic chondrocyte
phenotype. This Proof of Concept (PoC) study in OA patients evaluated
the effects of intraarticular (i.a.) rhFGF18 injection after single ascending
dose (SAD) and multiple ascending dose (MAD) regimens.
Methods: Eligible patients were ≥40 y with symptomatic primary
femorotibial OA of the target knee and radiological disease (Kellgren-
Lawrence grades 2 or 3), with no major knee surgery planned for
≥1 y after ﬁrst injection of study drug; stable oral OA treatments
were permitted. Patients received rhFGF18 or placebo, randomized 3:1
per cohort. Study drug was injected in 10mg, 30mg, or 100mg doses
either once (SAD) or once weekly for 3 weeks in 2 treatment cycles
(MAD). Follow-up and safety reviews occurred weekly over the 4 weeks
postinjection (both cohorts) and at weeks 8, 13, 14, 15, 17, 26, 39
and 52 postinjection (MAD cohorts). Efﬁcacy (MAD cohorts) included
assessment of knee cartilage in selected regions of interest by MRI exam,
joint space width (JSW) of target knee on X-ray, and function and pain
in target knee (WOMAC scores). MRI was performed with coronal SPGR
sequences at baseline, 12, 26, and 52 weeks; X-ray was performed in the
semiﬂexed position at baseline and 52 weeks. All cohorts were assessed
for local and systemic safety. SAD cohorts were assessed for systemic
exposure to rhFGF18.
Results: In SAD cohorts, 18 patients received rhFGF18; 6 received
placebo. In MAD cohorts, 126 received rhFGF18; 42 received placebo.
Age range was 41.4–84.9 y; the BMI range was 15.6–49.0 kg/m 2. As
measured in MAD cohorts, there was a signiﬁcant dose-dependent
anabolic effect of rhFGF18 on cartilage: for the total femorotibial cartilage
volume at 12 months, compared with placebo (−112.69±470.16mm3)
cartilage loss slowed with the lowest dose (−45.20±1117.3mm3), stopped
with the intermediate dose (−1.09±189.93mm3) and reversed with
the highest dose (52.68±175.7mm3; overall p-value=0.0251). Effects
